ENO4 Activators
ENO4 activators are a class of chemical compounds that interact with the biological enzyme ENO4, which is a putative member of the enolase family of proteins. Enolases are a key group of enzymes that are involved in the glycolytic pathway, catalyzing the conversion of 2-phosphoglycerate to phosphoenolpyruvate. However, ENO4 activators are not typical substrates or inhibitors; they modulate the activity of ENO4 through a non-canonical mechanism that alters the enzyme's conformation or its interaction with other molecules within the cell. The biochemical pathways and mechanisms of action pertaining to ENO4 are less characterized compared to other members of the enolase family, which makes the study of ENO4 activators a novel and intriguing area of chemical biology.
The specific molecular characteristics of ENO4 activators often include features that allow them to engage with the enzyme at allosteric sites, which are regions on the protein surface distinct from the active site where catalysis occurs. Binding at these allosteric locations can induce changes in the enzyme's structure that either enhance or diminish its catalytic activity, depending on the nature of the interaction and the conformational changes induced. ENO4 activators may thus have a significant impact on the metabolic flux through pathways that are interconnected with the enzymatic reaction that ENO4 catalyzes. The study of these activators sheds light on the subtle nuances of metabolic regulation and offers insights into the intricate network of enzymatic interactions that sustain cellular metabolism. Despite our growing understanding, much remains to be discovered about the specific molecular interactions and regulatory mechanisms that ENO4 activators engage in, making them a rich subject for research in the field of biochemistry and molecular biology.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin acts by elevating cAMP levels, which in turn activate PKA. PKA phosphorylates several targets, including enzymes and other proteins that can enhance the glycolytic activity of ENO4 by promoting its allosteric activation or stabilization of its active form. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which can phosphorylate multiple substrates involved in cellular metabolism, potentially increasing ENO4 activity by enhancing its interaction with other glycolytic enzymes. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate acts via G protein-coupled receptors to activate downstream kinases, which could lead to the post-translational modification of ENO4 thereby enhancing its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor that can indirectly upregulate ENO4 activity by inhibiting kinases that phosphorylate and deactivate proteins that compete with or negatively regulate ENO4. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent protein kinases that may phosphorylate and activate ENO4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that, by reducing PI3K/AKT pathway activity, could shift cellular metabolism towards glycolysis, thereby potentially enhancing ENO4 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that may increase ENO4 activity by inhibiting the ERK pathway, which can regulate metabolic enzyme activity, including enzymes involved in glycolysis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, and by inhibiting p38 MAPK, it could enhance glycolytic flux, potentially increasing the functional activity of ENO4. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that can upregulate calcium-dependent signaling pathways, potentially activating ENO4 by promoting its phosphorylation through calcium-sensitive kinases. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that could lead to the activation of ENO4 by inhibiting kinases that negatively regulate glycolysis or ENO4's activity. | ||||||